CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment
The company specializes in creating targeted approaches to address various types of malignancies, employing cutting-edge research and technology to enhance patient care. By leveraging their expertise in oncology, CG Oncology aims to provide meaningful advancements in treatment options and improve the overall outcomes for cancer patients. Through the development of novel drugs and therapies, CG Oncology is dedicated to addressing unmet medical needs in the fight against cancer.
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock.
CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects.
U.S. stocks were mixed, with the Nasdaq Composite trading almost flat on Monday. Shares of CymaBay Therapeutics, Inc. (NASDAQCBAY) rose sharply in today’s pre-market trading.
Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on Friday a dollar below that IPO price.
